CA3234233A1 - Endonuclease systems - Google Patents
Endonuclease systems Download PDFInfo
- Publication number
- CA3234233A1 CA3234233A1 CA3234233A CA3234233A CA3234233A1 CA 3234233 A1 CA3234233 A1 CA 3234233A1 CA 3234233 A CA3234233 A CA 3234233A CA 3234233 A CA3234233 A CA 3234233A CA 3234233 A1 CA3234233 A1 CA 3234233A1
- Authority
- CA
- Canada
- Prior art keywords
- endonuclease
- sequence
- seq
- engineered
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282999P | 2021-11-24 | 2021-11-24 | |
| US63/282,999 | 2021-11-24 | ||
| US202163289981P | 2021-12-15 | 2021-12-15 | |
| US63/289,981 | 2021-12-15 | ||
| US202263356908P | 2022-06-29 | 2022-06-29 | |
| US63/356,908 | 2022-06-29 | ||
| PCT/US2022/080437 WO2023097282A1 (en) | 2021-11-24 | 2022-11-23 | Endonuclease systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234233A1 true CA3234233A1 (en) | 2023-06-01 |
Family
ID=86540394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234233A Pending CA3234233A1 (en) | 2021-11-24 | 2022-11-23 | Endonuclease systems |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12410449B2 (enExample) |
| EP (1) | EP4437096A4 (enExample) |
| JP (1) | JP2024541402A (enExample) |
| KR (1) | KR20240110603A (enExample) |
| AU (1) | AU2022396533A1 (enExample) |
| CA (1) | CA3234233A1 (enExample) |
| MX (1) | MX2024006257A (enExample) |
| WO (1) | WO2023097282A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| CN121241133A (zh) * | 2023-03-31 | 2025-12-30 | 阿伯生物技术公司 | Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统 |
| WO2025117544A1 (en) * | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| CN117384884B (zh) * | 2023-11-30 | 2024-03-08 | 辉大(上海)生物科技有限公司 | IscB多肽及其用途 |
| CN117511912B (zh) * | 2023-12-22 | 2024-03-29 | 辉大(上海)生物科技有限公司 | IscB多肽、包含其的系统及其用途 |
| WO2025207709A1 (en) * | 2024-03-26 | 2025-10-02 | Arbor Biotechnologies, Inc. | Reverse transcription-mediated gene editing systems and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2015066119A1 (en) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| AU2016263026A1 (en) | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
| WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| TWI906646B (zh) | 2015-06-18 | 2025-12-01 | 美商博得學院股份有限公司 | 降低脫靶效應的ｃｒｉｓｐｒ酶突變 |
| WO2017106414A1 (en) | 2015-12-18 | 2017-06-22 | Danisco Us Inc. | Methods and compositions for polymerase ii (pol-ii) based guide rna expression |
| EP3423580A1 (en) | 2016-03-04 | 2019-01-09 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| EP3426780A1 (en) | 2016-03-11 | 2019-01-16 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| EP3500967A1 (en) | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| BR112019006388A2 (pt) | 2016-09-30 | 2019-06-25 | Univ California | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas |
| SG10201913505WA (en) | 2016-10-17 | 2020-02-27 | Univ Nanyang Tech | Truncated crispr-cas proteins for dna targeting |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| CA3048907C (en) | 2017-01-06 | 2023-05-23 | Nantkwest, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3617311B1 (en) | 2017-03-30 | 2024-11-20 | Kyoto University | Method for inducing exon skipping by genome editing |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| EP3625338A4 (en) | 2017-05-19 | 2021-01-20 | Tsinghua University | CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA |
| CN107164377A (zh) | 2017-06-12 | 2017-09-15 | 王小平 | 基于碱基编辑的基因敲除方法及其应用 |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| KR102465067B1 (ko) | 2018-02-15 | 2022-11-10 | 시그마-알드리치 컴퍼니., 엘엘씨 | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
| WO2019165168A1 (en) | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| CN112040987A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| AU2019252925A1 (en) | 2018-04-13 | 2020-07-30 | Sigma-Aldrich Co. Llc. | Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins |
| WO2020041120A1 (en) | 2018-08-20 | 2020-02-27 | Massachusetts Institute Of Technology | Robotic manipulation of objects using external contacts |
| WO2020055941A1 (en) * | 2018-09-13 | 2020-03-19 | Excision Biotherapeutics, Inc. | Compositions and methods for excision with single grna |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| EP3911735A4 (en) | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| US20220220460A1 (en) | 2019-02-14 | 2022-07-14 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CA3241703C (en) | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| US20220298494A1 (en) | 2019-02-14 | 2022-09-22 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| WO2021226363A1 (en) | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| JP2020154564A (ja) | 2019-03-19 | 2020-09-24 | 富士通株式会社 | 学習方法、学習プログラムおよび学習装置 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2021097118A1 (en) * | 2019-11-12 | 2021-05-20 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| WO2021202559A1 (en) * | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| EP4165177A4 (en) | 2020-05-08 | 2024-08-28 | Metagenomi, Inc. | ENZYMES WITH RUVC DOMAINS |
| JP2023540797A (ja) | 2020-09-11 | 2023-09-26 | メタゲノミ，インコーポレイテッド | 塩基編集酵素 |
| CN112126661B (zh) | 2020-09-30 | 2022-07-22 | 上海中医药大学 | 一种高效敲除nk细胞中tigit基因的方法 |
| JP2023546671A (ja) | 2020-10-23 | 2023-11-07 | ザ・ブロード・インスティテュート・インコーポレイテッド | 再プログラム可能なｉｓｃｂヌクレアーゼ及びその使用 |
| JP2024515936A (ja) | 2021-03-19 | 2024-04-11 | メタゲノミ，インク． | Ｃａｓ酵素を用いたマルチプレックス編集 |
| KR20240004618A (ko) | 2021-04-30 | 2024-01-11 | 메타지노미, 인크. | Ruvc 도메인을 갖는 효소 |
| EP4437095A1 (en) | 2021-11-24 | 2024-10-02 | Metagenomi, Inc. | Endonuclease systems |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
-
2022
- 2022-11-23 AU AU2022396533A patent/AU2022396533A1/en active Pending
- 2022-11-23 JP JP2024529294A patent/JP2024541402A/ja active Pending
- 2022-11-23 KR KR1020247019181A patent/KR20240110603A/ko active Pending
- 2022-11-23 MX MX2024006257A patent/MX2024006257A/es unknown
- 2022-11-23 EP EP22899556.9A patent/EP4437096A4/en active Pending
- 2022-11-23 WO PCT/US2022/080437 patent/WO2023097282A1/en not_active Ceased
- 2022-11-23 CA CA3234233A patent/CA3234233A1/en active Pending
-
2024
- 2024-05-21 US US18/669,712 patent/US12410449B2/en active Active
-
2025
- 2025-07-29 US US19/284,314 patent/US20260078412A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240294948A1 (en) | 2024-09-05 |
| EP4437096A4 (en) | 2025-09-24 |
| EP4437096A1 (en) | 2024-10-02 |
| WO2023097282A1 (en) | 2023-06-01 |
| AU2022396533A1 (en) | 2024-05-02 |
| US20260078412A1 (en) | 2026-03-19 |
| MX2024006257A (es) | 2024-07-29 |
| KR20240110603A (ko) | 2024-07-15 |
| JP2024541402A (ja) | 2024-11-08 |
| US12410449B2 (en) | 2025-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11946039B2 (en) | Class II, type II CRISPR systems | |
| US20240117330A1 (en) | Enzymes with ruvc domains | |
| US12410449B2 (en) | Endonuclease systems | |
| US12024727B2 (en) | Enzymes with RuvC domains | |
| US20240309404A1 (en) | Base editing enzymes | |
| EP4127155A1 (en) | Class ii, type ii crispr systems | |
| US20240409962A1 (en) | Endonuclease systems | |
| US20240352433A1 (en) | Enzymes with hepn domains | |
| CN118265783A (zh) | 核酸内切酶系统 | |
| HK40084708A (en) | Class ii, type ii crispr systems | |
| HK40084708B (en) | Class ii, type ii crispr systems | |
| GB2594339A (en) | Enzymes with RUVC Domains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED Effective date: 20250805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251111 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260216 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218 |
|
| R16 | Change to inventor recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260304 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20260311 |